SUBSCRIBE
SUBSCRIBE

OnCusp Therapeutics

NEWS
Pictured: Jar of money / Adobe Stock, juliasudnits
ADC-Focused OnCusp Therapeutics Emerges with $100M Series A Raise
Targeting the red hot antibody-drug conjugate market, OnCusp Therapeutics is coming out of the gate with $100 million from investors such as Novo Holdings and OrbiMed.
January 5, 2024
 · 
2 min read
 · 
Tyler Patchen
IN THE PRESS
Drug Development
OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
March 6, 2024
 · 
3 min read
Pharm Country
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients
January 4, 2024
 · 
4 min read
Drug Development
OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors
August 15, 2023
 · 
2 min read
OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023
April 11, 2023
 · 
2 min read
Business
OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate
June 8, 2022
 · 
4 min read
Business
OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies
June 29, 2021
 · 
6 min read
JOBS